#London #United Kingdom #Implantica #GERD #RefluxStop

Implantica Hosts UK RefluxStop™ Users Meeting

Implantica AG, a leading MedTech innovator in the acid reflux treatment space, successfully conducted its inaugural UK National Users Meeting last week. The meeting brought together 21 esteemed anti-reflux specialists to discuss the surging demand for RefluxStop™, particularly following the National Institute for Health and Care Excellence (NICE) granting favorable recommendations for its use in NHS public hospitals.

The gathering provided a platform for surgeons to engage in rich discussions about their experiences with the RefluxStop™ device, which addresses a significant issue faced by individuals suffering from gastroesophageal reflux disease (GERD). With an estimated one billion people globally affected by acid reflux, these recommendations open up substantial new opportunities for RefluxStop™ procedures in patients with compromised motility—a group that represents 40% to 50% of GERD sufferers.

Leading the discussions was Mr. Ahmed Ahmed, a prominent anti-reflux surgeon at the Imperial College Healthcare NHS Trust. "There is a noticeable increase in patient inquiries about RefluxStop™, a testament to its effectiveness. I'm excited to collaborate with my peers to offer the latest treatment alternatives for our GERD patients," he remarked. Ahmed emphasized the overwhelming support for RefluxStop™ within the UK healthcare system, highlighting the importance of NICE's recommendations for making innovative treatments readily available to patients in need.

Dr. Peter Forsell, the founder and CEO of Implantica, echoed these sentiments. He expressed his appreciation for NICE's thorough review process that culminated in favorable recommendations for RefluxStop™. Considering that nearly 20% of adults in the UK grapple with the persistent discomfort of GERD, these recommendations signal a critical response to an unmet medical need, particularly for those with impaired esophageal motility.

During the meeting, several UK surgeons presented their clinical outcomes and the satisfaction levels reported by patients who underwent the RefluxStop™ procedure. Their experiences highlight that the treatment is not only achieving positive medical results but also significantly improving patients' quality of life.

Dr. Forsell noted a widespread enthusiasm among UK surgeons and healthcare professionals regarding RefluxStop™, predicting that it will reshape the landscape of reflux treatment in the UK and potentially on a global scale in the foreseeable future.

RefluxStop™ is unique in its approach to treating acid reflux, differentiating itself from conventional surgical options that often come with a host of side effects such as pain during swallowing or the inability to belch. Instead, it focuses on preserving the natural anatomical structure of the lower esophageal sphincter, allowing the body to combat the issue of acid reflux effectively.

With the favorable momentum from both the medical community and healthcare policymakers, the future for RefluxStop™ looks promising. It is not only a potential game-changer for reflux surgery but also a beacon of hope for millions dealing with GERD. As global interest in innovative medical technologies continues to rise, RefluxStop™ stands out as a promising solution backed by proven clinical results, setting the stage for a new era in reflux management.

For more information about Implantica and its innovative products, visit www.implantica.com.